|
1
|
Kgatle MM, Kalla AA, Islam MM, Sathekge M
and Moorad R: Prostate cancer: Epigenetic alterations, risk factors
and therapy. Prostate Cancer. 2016:56538622016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Silvestri I, Cattarino S, Giantulli S,
Nazzari C, Collalti G and Sciarra A: A perspective of immunotherapy
for prostate cancer. Cancers (Basel). 8:E642016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thakur A, Vaishampayan U and Lum LG:
Immunotherapy and immune evasion in prostate cancer. Cancers.
5:569–590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Strasner A and Karin M: Immune
infiltration and prostate cancer. Front Oncol. 5:1282015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hogquist KA, Jameson SC, Heath WR, Howard
JL, Bevan MJ and Carbone FR: T cell receptor antagonist peptides
induce positive selection. Cell. 76:17–27. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dudley DJ: The immune system in health and
disease. Baillieres Clin Obstet Gynaecol. 6:393–416. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Risitano AM, Maciejewski JP, Green S,
Plasilova M, Zeng W and Young NS: In-vivo dominant immune responses
in aplastic anaemia: Molecular tracking of putatively pathogenetic
T-cell clones by TCR beta-CDR3 sequencing. Lancet. 364:355–364.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calis JJ and Rosenberg BR: Characterizing
immune repertoires by high throughput sequencing: Strategies and
applications. Trends Immunol. 35:581–590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Zhang D, Yan W, Yang D and Shen B:
Translational bioinformatics for diagnostic and prognostic
prediction of prostate cancer in the next-generation sequencing
era. Biomed Res Int. 2013:9015782013.PubMed/NCBI
|
|
10
|
Serrati S, De Summa S, Pilato B, Petriella
D, Lacalamita R, Tommasi S and Pinto R: Next-generation sequencing:
Advances and applications in cancer diagnosis. Onco Targets Ther.
9:7355–7365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robins H: Immunosequencing: Applications
of immune repertoire deep sequencing. Curr Opin Immunol.
25:646–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hou XL, Wang L, Ding YL, Xie Q and Diao
HY: Current status and recent advances of next generation
sequencing techniques in immunological repertoire. Genes Immun.
17:153–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mirshahidi S, Ferris LC and Sadegh-Nasseri
S: The magnitude of TCR engagement is a critical predictor of T
cell anergy or activation. J Immunol. 172:5346–5355. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lefranc MP: Immunoglobulin and T cell
receptor genes: IMGT (®) and the birth and rise of
immunoinformatics. Front Immunol. 5:222014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou X, Lu C, Chen S, Xie Q, Cui G, Chen J,
Chen Z, Wu Z, Ding Y, Ye P, et al: High throughput sequencing of T
cell antigen receptors reveals a conserved TCR repertoire. Medicine
(Baltimore). 95:e28392016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sui W, Hou X, Zou G, Che W, Yang M, Zheng
C, Liu F, Chen P, Wei X, Lai L and Dai Y: Composition and variation
analysis of the TCR β-chain CDR3 repertoire in systemic lupus
erythematosus using high-throughput sequencing. Mol Immunol.
67:455–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arap W, Trepel M, Zetter BR and Pasqualini
R: Meeting report: Innovations in prostate cancer research. Cancer
Res. 68:635–638. 2008.PubMed/NCBI
|
|
18
|
Magurran AE: Ecology: Linking species
diversity and genetic diversity. Curr Biol. 15:R597–R599. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ebelt K, Babaryka G, Frankenberger B,
Stief CG, Eisenmenger W, Kirchner T, Schendel DJ and Noessner E:
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+
lymphocyte clusters. Eur J Cancer. 45:1664–1672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Valdman A, Jaraj SJ, Compérat E, Charlotte
F, Roupret M, Pisa P and Egevad L: Distribution of Foxp3-, CD4- and
CD8-positive lymphocytic cells in benign and malignant prostate
tissue. APMIS. 118:360–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Derhovanessian E, Adams V, Hähnel K,
Groeger A, Pandha H, Ward S and Pawelec G: Pretreatment frequency
of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with
clinical response to whole-cell vaccination in prostate cancer
patients. Int J Cancer. 125:1372–1379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garcia AJ, Ruscetti M, Arenzana TL, Tran
LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale
ST and Wu H: Pten null prostate epithelium promotes localized
myeloid-derived suppressor cell expansion and immune suppression
during tumor initiation and progression. Mol Cell Biol.
34:2017–2028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Di Mitri D, Toso A, Chen JJ, Sarti M,
Pinton S, Jost TR, D'Antuono R, Montani E, Garcia-Escudero R,
Guccini I, et al: Tumour-infiltrating Gr-1+ myeloid cells
antagonize senescence in cancer. Nature. 515:134–137. 2014.
View Article : Google Scholar : PubMed/NCBI
|
